By IDSE News Staff
Current or previous use of the antiretroviral (ARV) drug abacavir was associated with an elevated risk for major adverse cardiovascular events (MACE) in people with HIV, according to an exploratory analysis from a large international clinical trial that was presented at AIDS 2024, in Munich.
There was no elevated MACE risk for the other ARVs included in the analysis.